AGENDA DAY 3

 

Day 3 Oct 12th Veterinary

Catherine Charreyre
09:10

Developing veterinary vaccines for emerging and re-emerging diseases: gaps and requirements

 
  • Key considerations when launching a veterinary vaccine development programme
  • Highlighting the constraints that are enforced by national and European regulatory authorities and provide obstacles to obtaining market authorisation
  • Promising areas of development
Thierry Van Den Berg
09:40

A transboundary problem: Lumpy Skin Disease (LSD)


  • Reviewing the current spread of the disease and the role of the vectors and the environmental factors in the epidemiology of the disease
  • Addressing the vital issue of vaccination against lumpy skin disease. Is vaccination the most effective control method?
  • How can Europe effectively deal with this re-emerging challenge?
Dr Arnaud Bataille
10:10

Peste des Petits Ruminants: state of affairs and the road towards eradication

  • Review of our knowledge of PPR epidemiology and the threat of this disease to Europe
  • Recent and on-going research of major importance for the success of the eradication, notably on vaccine development
  • Major gaps in our knowledge of this disease and how those could hinder the global eradication effort
10:40

Networking Break

Prof Martin Vordermeier
11:20

Application of DIVA vaccines to address Bovine Tuberculosis in Cattle

 
  • Discussing progress made on optimizing the only potentially available vaccine, bacille Calmette Guérin (BCG)
  • What strategies are there to improve BCG efficacy?
  • Highlighting recent advances in DIVA development based on the detection of host cellular immune responses by blood-testing or skin-testing approaches
  • What are the next steps necessary in order to accelerate DIVA vaccine development?
Dr Peter Daszak
11:50

The Global Virome Project: Bringing an end to pandemics

 
  • Sharing progressive updates on the rapid response to quickly produce several effective vaccines
  • Challenges faced, steps taken to overcome these and thoughts for future emerging disease outbreaks.  
12:20

Networking Lunch

Dr Richard Mole
13:20

The quest to develop new and improved vaccines for a range of economically important livestock diseases

 
  • Research and data updates in line with Moredun’s veterinary vaccine research
  • Sharing information on development portfolio for vaccines for a range of endemic diseases, particularly parasitic diseases
  • Case study: Barbervax, a vaccine against Haemonchus gastrointestinal worms in sheep 
Panel discussion
13:50

Fast track licensing: rapid registration of novel vaccine platforms panel

 
  • Industry and regulatory perspectives
  • Addressing acceleration of the licensing and registration process for new vet tech
  • Hear from a company who has successfully registered a novel vaccine platform through fast track licensing.
  • Discussing current challenges, hurdles faced, challenges overcome and thoughts for future
Additional panellists to be confirmed shortly..
Dr Alicia Urniza, Director EU Biologicals, VMRD, Zoetis
Jean de Foucauld
14:50

Increasing availability of veterinary medicinal products through harmonisation of national regulation regarding autogeneous farm specific vaccines

 
  • The need to harmonise requirements and the understanding of “in the same locality”, regarding the concept of epidemiological links between farms
  • Discussing the importance of defining good practices regarding the manufacture and control of autogenous vaccines
  • Considering potential implementation strategies to incorporate harmonisation within legislative framework
Gillian Cowan
15:20

Harmonisation of registration requirements for veterinary vaccines in East Africa and a regional, time-based Mutual Recognition Procedure

 
  • Harmonising technical requirements
  • Development of a Mutual Recognition Procedure (MRP)
  • Implementing MRP in the East African Community
15:50

Chair’s closing remarks and close of Congress

last published: 05/Oct/17 16:46 GMT